MARCO CIPPITELLI

Dr. Marco Cippitelli. Curriculum Vitae et Studiorum
Education and professional experience
1990. Graduated in Biological Science (summa cum laude), University of Rome "La Sapienza".
1992-1995. Visiting Scientist at the "Biological Carcinogenesis and Development Program, “Molecular Immunology Section" (Laboratory of Experimental Immunology) National Cancer Institute (NCI) Frederick, Maryland, USA.
1996. PhD, University of Rome "La Sapienza".
1996-2000. Research Scientist at the Laboratory of Immunology (Dept. Experimental Medicine and Pathology) and Laboratory of Pathophysiology, CRS, Regina Elena, Rome.
2000-2007. Researcher-Lecturer - General Pathology (Med-04), Dept. of Experimental Medicine
and Pathology, University of Rome "La Sapienza".
2007-2021. Associate Professor - General Pathology (Med-04), Dept. of Molecular Medicine, University of Rome "La Sapienza".
2022. Full Professor - General Pathology (Med-04), Dept. of Molecular Medicine, University of Rome "La Sapienza".
--
Dr. Cippitelli research activity has been mainly conducted in the field of transcriptional regulation and tumor immunology, aimed at understanding the mechanisms underlying the regulation of genes involved in NK cell antitumor effector functions.
- Author of original publications in high rank journals.
- Member of the Italian Society of Immunology, Clinical Immunology and Allergology (S.I.I.C.A.) - Referee of different international journals such as: Journal of Immunology, European Journal of Immunology, Immunology letters, Haematologica, Molecular Pharmacology, International Journal of Medical Sciences, Oncotarget, Annals of Hematology, Carcinogenesis, Cancers, Cells, Molecular Cancer.
- Lecturer in Immunology and Immunopathology, General Pathology (Faculty of Pharmacy and Medicine University of Rome - La Sapienza, Italy).
- Supervisor of Graduate Students, PhD Students and Postdoctoral Fellows.

Dr. Marco Cippitelli - Main Bibliometric Indicators:
H index: 39 (Scopus)
Citations: 5200 (Scopus)
ORCID ID: orcid.org/0000-0002-9620-538X
--

Laboratory setting:
Dr. Cippitelli works at the Department of Molecular Medicine, University of Rome - Sapienza, Rome - Italy.
The laboratory is fully equipped for cellular and molecular biology/immunology studies and shares with other labs in the Department high-tech equipment and core facilities (flow-cytometry, cell sorting, qReal-Time PCR, microscopy platform-confocal, Single-Cell, Orbitrap Mass-Spec.).

Dr. Marco Cippitelli - Curriculum Vitae et Studiorum.

Academic profile:

Full Professor of General Pathology at the Department of Molecular Medicine, Sapienza University of Rome, with longstanding expertise in molecular immunology, transcriptional regulation, tumor immunology, and NK-cell biology. His research focuses on the molecular mechanisms controlling immune effector functions, tumor immune recognition, and stress-dependent modulation of cancer cell susceptibility to Natural Killer (NK) cell-mediated responses.
His early work contributed to the characterization of transcriptional pathways regulating IFN-gamma, IL-2, IL-4, FasL, TRAIL, and RANK-L genes in T lymphocytes, with particular emphasis on NF-AT, NF-kappaB, AP-1/CREB-ATF transcription factors, nuclear receptors, and cytokine- and receptor-mediated signaling. He also investigated integrin-dependent activation of IFN-gamma transcription in NK cells, and the immunomodulatory effects of vitamin D3, PPAR-gamma ligands, and hyperthermia.
Over the last decade, his research has focused primarily on tumor immunology and NK-cell antitumor responses in hematologic malignancies, particularly multiple myeloma. Major research lines include the regulation of NKG2D and DNAM-1 ligands by therapeutic agents, mechanisms controlling NK-cell recognition and cytotoxicity, tumor stress pathways that enhance immune susceptibility, neddylation-dependent immunoregulation, and nucleolar stress responses. Current work addresses the immunoregulatory role of EIF4A3 and RNA metabolism in multiple myeloma, with emphasis on ribosome biogenesis, RNA splicing, translational control, stress adaptation, and NK-cell antitumor activity.

Bibliometric indicators and identifiers:
H-index 40 (Scopus)
Citations 5,550 (Scopus)

ORCID: orcid.org/0000-0002-9620-538X

Education and academic appointments:
1990 Degree in Biological Sciences, summa cum laude, University of Rome "La Sapienza", Rome, Italy.
1992-1995 Visiting Scientist, Molecular Immunology Section, Laboratory of Experimental Immunology, Biological Carcinogenesis and Development Program, National Cancer Institute (NCI), Frederick, Maryland, USA.
1996 PhD in Experimental Medicine, University of Rome "La Sapienza", Rome, Italy.
1996-2000 Research Scientist, Laboratory of Immunology, Department of Experimental Medicine and Pathology, and Laboratory of Pathophysiology, Centro Ricerche Sperimentali, Regina Elena Cancer Institute, Rome, Italy.
2000-2007 Researcher-Lecturer in General Pathology (MED/04), Department of Experimental Medicine and Pathology, University of Rome "La Sapienza", Rome, Italy.
2000-2012 Research Associate Scientist, Laboratory of Pathophysiology, Centro Ricerche Sperimentali, Regina Elena Cancer Institute, Rome, Italy.
2007-2021 Associate Professor of General Pathology (MED/04), Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
2022-present Full Professor of General Pathology, MEDS-02/A (formerly MED/04), Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Academic roles, service, and supervision:
• Author of peer-reviewed publications in high-ranking international journals in immunology, molecular oncology, and cancer biology.
• Member of the Italian Society of Immunology, Clinical Immunology and Allergology (S.I.I.C.A.).
• Referee for international journals including Journal of Immunology, European Journal of Immunology, Immunology Letters, Haematologica, Molecular Pharmacology, International Journal of Medical Sciences, Oncotarget, Annals of Hematology, Carcinogenesis, Cancers, Cells, and Molecular Cancer.
• Lecturer in Immunology, Immunopathology, and General Pathology within the Faculty of Pharmacy and Medicine, Sapienza University of Rome.
• Supervisor of graduate students, PhD students, and postdoctoral fellows.

Research expertise and scientific trajectory:
Dr. Cippitelli's research activity has been mainly conducted in transcriptional regulation, immunomodulation, tumor immunology, and NK-cell biology, with a sustained focus on the mechanisms underlying the regulation of genes involved in antitumor effector functions.

Main areas of interest:
1992-1995 Transcriptional regulation of IFN-gamma, IL-2, and IL-4 genes in activated T cells, including the roles of AP-1/CREB-ATF, NF-AT, and NF-kappaB transcription factors. These studies contributed to the understanding of intracellular pathways governing cytokine gene regulation in T lymphocytes.
1996-1998 Molecular mechanisms modulating IFN-gamma and IL-12 gene transcription through vitamin D3 nuclear receptor signaling in T cells and monocytes/dendritic cells.
1996-1998 Signaling pathways involved in integrin receptor-mediated activation of IFN-gamma gene transcription in NK cells.
1996-1998 Role of the anti-apoptotic protein Bcl-2 in the regulation of NF-kappaB transcriptional activity and MMP-9 metalloproteinase gene expression in human breast carcinoma cells.
2000-2003 Transcriptional and functional regulation of the FasL/CD95L gene in activated T cells by nuclear receptors and specific ligands, including calcitriol/vitamin D3 receptor (VDR) signaling and PPAR-gamma activators.
2003-2005 Molecular mechanisms by which hyperthermia enhances FasL gene transcription in activated T cells.
2005-2007 Regulation of RANK-L and TRAIL gene transcription and function in activated T cells by nuclear receptors and PPAR-gamma activators.
2007-2017 Molecular mechanisms regulating the transcription, expression, and function of NKG2D and DNAM-1 ligands in multiple myeloma cells exposed to therapeutic agents.
2018-2022 Characterization of neddylation as a post-translational immunoregulatory pathway controlling NK-cell recognition and killing of cancer cells.
2023-2024 Investigation of nucleolar stress responses in multiple myeloma and their regulatory activity in NK-cell recognition and cytotoxicity.
2025-2026 Immunoregulatory role of EIF4A3 (Eukaryotic Initiation Factor 4A-III) in multiple myeloma, with focus on RNA binding and helicase activity, the Exon Junction Complex, mRNA splicing, translation efficiency, and nonsense-mediated decay.

Significant career developments and research focus:
• Definition of transcription factor networks regulating key immune genes in T lymphocytes, including IFN-gamma, IL-2, IL-4, FasL, TRAIL, and RANK-L.
• Mechanistic analysis of nuclear receptor-dependent immunomodulation, particularly vitamin D3/VDR and PPAR-gamma pathways.
• Investigation of NK-cell activating receptor ligand regulation in multiple myeloma and the conversion of tumor cells into NK-permissive states.
• Study of post-translational modifications, including neddylation, as immunoregulatory mechanisms in tumor recognition.
• Analysis of nucleolar stress and RNA metabolism pathways as determinants of NK-cell antitumor activity in multiple myeloma.

Fellowships and financial support:
Fellowships
• Postdoctoral Grant Fellowship (PRI Scientist), Biological Carcinogenesis and Development Program, National Cancer Institute (NCI), Frederick, Maryland, USA, 1992-1995.
• Fondazione Cenci Bolognetti - Pasteur Institute Italy Postdoctoral Grant Fellowship, 1996 call.
• Regina Elena Cancer Institute, Italy, Postdoctoral Grant Fellowship, 1997-2000.

Selected funded projects:
2001-2003 Ministry of Health project: "Identification of molecules involved in oxidative stress as targets for antitumor therapy". Coordinator: Dr. Gabriella Zupi, Regina Elena Cancer Institute, CRS, Rome, Italy.
2001-2002 CNR - Agenzia 2000 program: "Transcriptional regulation of the cell cycle: role of Rb and co-regulatory signals". Coordinator: Prof. Alberto Gulino, University of Rome "La Sapienza", Rome, Italy.
2003-2005 Ministry of Health project: "Phenotypic and molecular alterations associated with the response to hormonal therapies in patients with breast carcinoma". Coordinator: Dr. Marcella Mottolese, Regina Elena Cancer Institute, CRS, Rome, Italy.
2006-2008 Ministry of University, PRIN: "Analysis of GITR gene expression in T lymphocytes and specific pharmacological modulation". Coordinator: Prof. Carlo Riccardi, University of Perugia, Italy.
2008-2010 Ministry of University, PRIN: "Microenvironment and responses to therapy in multiple myeloma: alteration of pathologic osteoclastogenic potential". Coordinator: Prof. Antonio Sica, University of Piemonte Orientale "Amedeo Avogadro", Vercelli, Italy.
2010-2013 Ministry of University, PRIN: "Multiple Myeloma Immune Microenvironment as Target to Understand and Overcome Mechanisms of Clinical Relapse and Resistance". Coordinator: Prof. Angelo Vacca, University of Bari "Aldo Moro", Italy.
2017 Ministry of University, PRIN: "RNASET2 as a new player in the modulation of the innate immune system in cancer and autoimmunity: potential diagnostic and therapeutic implications". Coordinator: Prof. Douglas Noonan, University of Insubria, Italy.
2019-2021 Sapienza University, Progetti di Ricerca Grandi Ateneo: "Harnessing NK cells by genetic and epigenetic rerouting to overcome multiple myeloma immune evasion".
2022-2024 Sapienza University, Progetti di Ricerca Medi Ateneo: "Inhibition of neddylation as a strategy to boost NK-cell responses against multiple myeloma".
2023-2025 Sapienza University, Progetti di Ricerca Grandi Ateneo: "RNA Polymerase I inhibition and activation of nucleolar stress response in the anticancer activity of Natural Killer cells against multiple myeloma".
2022-2025 Ministry of University, PRIN: "Strategies to boost NK-cell responses against cancer by regulation of NK-cell activating ligands, death receptors and effector activity". Coordinator: Prof. Marco Cippitelli, Sapienza University of Rome, Italy.
2025-2027 Pasteur Institute Italy - Cenci Bolognetti Foundation: "RNA Polymerase I inhibition and activation of nucleolar stress response in the anticancer activity of Natural Killer cells against multiple myeloma". Coordinator: Prof. Marco Cippitelli, Sapienza University of Rome, Italy.

Laboratory setting and collaborations:
Dr. Cippitelli works at the Department of Molecular Medicine, Sapienza University of Rome. The laboratory is equipped for cellular and molecular biology and immunology studies and has access to departmental high-technology platforms and core facilities, including flow cytometry, cell sorting, quantitative real-time PCR, microscopy and confocal imaging, single-cell technologies, and Orbitrap mass spectrometry.
2010-present Ongoing collaboration with Dr. Maria Teresa Petrucci and Dr. Francesca Fazio, clinicians at Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, for diagnosis and follow-up of multiple myeloma patients according to SWOG diagnostic criteria and for biological sample collection.
2019-2023 Member of the Teaching Quality Assurance and Annual Monitoring Committee for the Bachelor's Degree Program in Biomedical Laboratory Techniques, Sapienza University of Rome.

Undergraduate and graduate teaching:
2001-present Lecturer in Immunology within the integrated course Clinical Pathology and Pathophysiological Bases of Disease, Bachelor's Degree Program in Biomedical Laboratory Techniques, Sapienza University of Rome.
2011-present Lecturer in General Pathology within the integrated course Cellular and Molecular Bases of Life, Bachelor's Degree Program in Neurophysiopathology Techniques, Sapienza University of Rome.
2007-present Coordinator and Lecturer in Immunology and Immunopathology (MD Program), Single-Cycle Master's Degree in Medicine and Surgery, Sapienza University of Rome.
2017-present Lecturer in Advances in General Pathology within the integrated course Methodology of Care Processes, Pain Therapy and Palliative Care; Course Coordinator, Sapienza University of Rome.
Academic year 2000/2001-present Member of the Faculty Board and contributor to teaching and tutoring activities within the PhD Program in Immunological Sciences / Innovation in Immuno-Mediated and Hematological Disorders.

Selected relevant publications from the last ten years:

The following publications were selected from the source CV as relevant outputs from the last ten years, with emphasis on tumor immunology, NK-cell biology, multiple myeloma, immune receptor ligands, and stress-response pathways.

1. Sproviero E, Gnocchini E, Cipollone T, Petillo S, Cassone C, Molfetta R, Zingoni A, Soriani A, Cerboni C, Petrucci MT, Fazio F, Paolini R, Palmieri G, Cippitelli M. Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma. Cell Death Dis. 2025 Nov 28;16(1):865. doi: 10.1038/s41419-025-08196-6.

2. Tassinari V, Kaciulis M, Petrai S, Stabile H, Pernazza A, Leopizzi M, Di Maio V, Belleudi F, Ranieri D, Mancini V, Palaia I, Tanzi F, Lospinoso Severini L, Ruggeri S, Greco ME, Bernardini G, Zingoni A, Cippitelli M, Cerboni C, Soriani A. ADAR1 expression is associated with cervical cancer progression and negatively regulates NK cell activity. JCI Insight. 2025 Jul 8;10(13):e190244. doi: 10.1172/jci.insight.190244.

3. Marangio C, Milito ND, Putro E, Carnevale A, Capuano C, Zingoni A, Cippitelli M, Santoni A, Paolini R, Molfetta R. NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells. Front Immunol. 2025 May 12;16:1575059. doi: 10.3389/fimmu.2025.1575059.

4. Cuollo L, Di Cristofano S, Sandomenico A, Iaccarino E, Oliver A, Zingoni A, Cippitelli M, Fionda C, Petillo S, Kosta A, Tassinari V, Petrucci MT, Fazio F, Menotti R, Santoni A, Raimondo D, Soriani A. CD38 restrains the activity of extracellular cGAMP in a model of multiple myeloma. iScience. 2024 Apr 25;27(5):109814. doi: 10.1016/j.isci.2024.109814.

5. Zingoni A, Antonangeli F, Sozzani S, Santoni A, Cippitelli M, Soriani A. The senescence journey in cancer immunoediting. Mol Cancer. 2024 Apr 1;23(1):68. doi: 10.1186/s12943-024-01973-5. Corresponding author: M. Cippitelli.

6. Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R, Fionda C, Soriani A, Cerboni C, Petrucci MT, Fazio F, Paolini R, Santoni A, Cippitelli M. NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells. Cell Death Dis. 2023 Jul 17;14(7):438. doi: 10.1038/s41419-023-05949-z.

7. Molfetta R, Petillo S, Cippitelli M, Paolini R. SUMOylation and related post-translational modifications in natural killer cell anti-cancer responses. Front Cell Dev Biol. 2023 May 25;11:1213114. doi: 10.3389/fcell.2023.1213114.

8. Vulpis E, Loconte L, Cassone C, Antonangeli F, Caracciolo G, Masuelli L, Fazio F, Petrucci MT, Fionda C, Soriani A, Cerboni C, Cippitelli M, Santoni A, Zingoni A. Cross-dressing of multiple myeloma cells mediated by extracellular vesicles conveying MIC and ULBP ligands promotes NK cell killing. Int J Mol Sci. 2023 May 30;24(11):9467. doi: 10.3390/ijms24119467.

9. Vulpis E, Cuollo L, Borrelli C, Antonangeli F, Masuelli L, Cippitelli M, Fionda C, Caracciolo G, Petrucci MT, Santoni A, Zingoni A, Soriani A. Doxorubicin-mediated miR-433 expression on exosomes promotes bystander senescence in multiple myeloma cells in a DDR-independent manner. Int J Mol Sci. 2023 Apr 6;24(7):6862. doi: 10.3390/ijms24076862.

10. Cippitelli M, Stabile H, Kosta A, Petillo S, Lucantonio L, Gismondi A, Santoni A, Fionda C. Role of NF-kappaB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci. 2023 Jan 17;24(3):1823. doi: 10.3390/ijms24031823.

11. Milito ND, Zingoni A, Stabile H, Soriani A, Capuano C, Cippitelli M, Gismondi A, Santoni A, Paolini R, Molfetta R. NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms. Eur J Immunol. 2023 Feb;53(2):e2250198. doi: 10.1002/eji.202250198.

12. Kosta A, Mekhloufi A, Lucantonio L, Zingoni A, Soriani A, Cippitelli M, Gismondi A, Fazio F, Petrucci MT, Santoni A, Stabile H, Fionda C. GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells. Front Immunol. 2022 Jul 28;13:942640. doi: 10.3389/fimmu.2022.942640.

13. Vulpis E, Loconte L, Peri A, Molfetta R, Caracciolo G, Masuelli L, Tomaipitinca L, Peruzzi G, Petillo S, Petrucci MT, Fazio F, Simonelli L, Fionda C, Soriani A, Cerboni C, Cippitelli M, Paolini R, Bernardini G, Palmieri G, Santoni A, Zingoni A. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: dual role in cancer immunosurveillance. J Extracell Vesicles. 2022 Jan;11(1):e12176. doi: 10.1002/jev2.12176.

14. Petillo S, Capuano C, Molfetta R, Fionda C, Mekhloufi A, Pighi C, Antonangeli F, Zingoni A, Soriani A, Petrucci MT, Galandrini R, Paolini R, Santoni A, Cippitelli M. Immunomodulatory effect of NEDD8-activating enzyme inhibition in multiple myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. Cell Death Dis. 2021;12(9):836.

15. Fionda C, Stabile H, Molfetta R, Kosta A, Peruzzi G, Ruggeri S, Zingoni A, Capuano C, Soriani A, Paolini R, Gismondi A, Cippitelli M, Santoni A. Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation. Eur J Immunol. 2021 Aug 15. doi: 10.1002/eji.202149269.

16. Cippitelli M, Stabile H, Kosta A, Petillo S, Gismondi A, Santoni A, Fionda C. Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them. Int J Mol Sci. 2021 Jan 22;22(3):1103. doi: 10.3390/ijms22031103.

17. Bilotta MT, Petillo S, Santoni A, Cippitelli M. Liver X receptors: regulators of cholesterol metabolism, inflammation, autoimmunity, and cancer. Front Immunol. 2020 Nov 3;11:584303. doi: 10.3389/fimmu.2020.584303.

18. Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A, Cippitelli M, Paolini R, Gismondi A, Ricciardi MR, Petrucci MT, Masuelli L, Caracciolo G, Palchetti S, Santoni A, Fionda C. Bone marrow stromal cell-derived IL-8 upregulates PVR expression on multiple myeloma cells via NF-kappaB transcription factor. Cancers (Basel). 2020 Feb 13;12(2):440. doi: 10.3390/cancers12020440.

19. Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, Cippitelli M, Gismondi A, Santoni A, Paolini R. CD155: a multi-functional molecule in tumor progression. Int J Mol Sci. 2020 Jan 30;21(3):922. doi: 10.3390/ijms21030922.

20. Fionda C, Stabile H, Cerboni C, Soriani A, Gismondi A, Cippitelli M, Santoni A. Hitting more birds with a stone: impact of TGF-beta on ILC activity in cancer. J Clin Med. 2020 Jan 5;9(1):143. doi: 10.3390/jcm9010143.

21. Acquati F, Mortara L, De Vito A, Baci D, Albini A, Cippitelli M, Taramelli R, Noonan DM. Innate immune response regulation by the human RNASET2 tumor suppressor gene. Front Immunol. 2019 Nov 5;10:2587. doi: 10.3389/fimmu.2019.02587.

22. Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R.

23. Fionda C, Di Bona D, Kosta A, Stabile H, Santoni A, Cippitelli M. The POU-domain transcription factor Oct-6/POU3F1 as a regulator of cellular response to genotoxic stress. Cancers (Basel). 2019 Jun 11;11(6):810. doi: 10.3390/cancers11060810.

24. Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, Cippitelli M, Santoni A, Paolini R. The ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing. Eur J Immunol. 2019 Jun;49(6):873-883. doi: 10.1002/eji.201847848.

25. Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in multiple myeloma: modulation by bromodomain and extra-terminal (BET) protein inhibitors. Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.

26. Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A. Key role of the CD56lowCD16low Natural Killer cell subset in the recognition and killing of multiple myeloma cells. Cancers (Basel). 2018 Nov 29;10(12):473. doi: 10.3390/cancers10120473.
27. Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A. Translating the anti-myeloma activity of Natural Killer cells into clinical application. Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005.

28. Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, Masuelli L, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A. Drug-induced senescent multiple myeloma cells elicit NK cell proliferation by direct or exosome-mediated IL15 trans-presentation. Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604.

29. Zingoni A, Vulpis E, Cecere F, Amendola MG, Fuerst D, Saribekyan T, Achour A, Sandalova T, Nardone I, Peri A, Soriani A, Fionda C, Mariggio E, Petrucci MT, Ricciardi MR, Mytilineos J, Cippitelli M, Cerboni C, Santoni A. MICA-129 dimorphism and soluble MICA are associated with the progression of multiple myeloma. Front Immunol. 2018 May 1;9:926. doi: 10.3389/fimmu.2018.00926.

30. Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A. NKG2D and its ligands: "one for all, all for one". Front Immunol. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476.

31. Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural Killer cell response to chemotherapy-stressed cancer cells: role in tumor immunosurveillance. Front Immunol. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194.

32. Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, Cippitelli M, Gismondi A, Santoni A, Paolini R. Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells. Sci Rep. 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0.
33. Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A. Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: role of HSP70/TLR2/NF-kappaB axis. Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372.

34. Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A. p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564.

35. Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J Hematol Oncol. 2016 Dec 1;9(1):134. doi: 10.1186/s13045-016-0362-2.

36. Pignoloni B, Fionda C, Dell'Oste V, Luganini A, Cippitelli M, Zingoni A, Landolfo S, Gribaudo G, Santoni A, Cerboni C. Distinct roles for human cytomegalovirus immediate early proteins IE1 and IE2 in the transcriptional regulation of MICA and PVR/CD155 expression. J Immunol. 2016 Nov 15;197(10):4066-4078. doi: 10.4049/jimmunol.1502527.

37. Zingoni A, Vulpis E, Nardone I, Soriani A, Fionda C, Cippitelli M, Santoni A. Targeting NKG2D and NKp30 ligand shedding to improve NK cell-based immunotherapy. Crit Rev Immunol. 2016;36(6):445-460. doi: 10.1615/CritRevImmunol.2017020166.

38. Fionda C, Abruzzese MP, Santoni A, Cippitelli M. Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer. Curr Med Chem. 2016;23(24):2618-2636. doi: 10.2174/0929867323666160727105101.